News | September 17, 2007

FDA Approves Radiofrequency Wireless ICD, CRT-D Heart Failure Devices

September 18, 2007 - St. Jude Medical Inc. announced FDA approval of its first radiofrequency (RF) wireless devices to treat patients with heart failure and with potentially lethal heart arrhythmias. The Promote RF CRT-D (cardiac resynchronization therapy defibrillator) and Current RF ICD (implantable cardioverter defibrillator) feature radiofrequency telemetry for wandless communication with programmers used by physicians to interrogate and program devices.

RF telemetry is designed to enable secure, remote communication between the implanted device and the programmers in a clinician's office or hospital. Wireless communication occurs while the device is being implanted and when patients see physicians for follow-up visits, allowing for efficient, more convenient care and device management.

The devices use a dedicated range of frequencies designated for medical devices called the MICS (Medical Implant Communications Service) frequency band, which helps to prevent interference from other electronic signals. The MICS technology also includes the capability to choose between 10 channels in order to optimize the telemetry link and avoid interference.

The Promote RF CRT-D and Current RF ICD are built on St. Jude Medical’s next generation Unity device platform. This consolidated electronics platform is engineered to enable St. Jude Medical to more quickly introduce devices with new features and diagnostics, as they become available, because the basic platform for all of the devices is the same. In addition, the consolidated platform’s expanded capabilities can reportedly support more advanced algorithms and features. All software interfaces for new St. Jude Medical pacemakers, ICDs and CRT devices will be the same.

The Promote RF CRT-D reportedly allows physicians to electronically reconfigure left ventricular (LV) leads to help optimize the pacing performance of the device without the need to physically reposition the lead.

In addition, the devices feature the VIP (Ventricular Intrinsic Preference) algorithm that is designed to allow the patient’s own heart rhythm to prevail when possible. VIP technology actively monitors the heart on a beat-by-beat basis to provide pacing only when needed, which has been shown to be better for patients’ overall heart health.

Related Content

ICD Placements Not Meeting Medicare Coverage Criteria Decline After Overuse Investigation Announced
Feature | Implantable Cardioverter Defibrillator (ICD) | July 11, 2018
Placement of implantable cardioverter defibrillators (ICDs) not meeting Centers for Medicare and Medicaid Services (CMS...
New Tool Predicts Benefits and Risks of Implantable Defibrillator for Heart Failure Patients
News | Implantable Cardioverter Defibrillator (ICD) | July 02, 2018
University of Washington (UW) Medicine cardiologists have developed a tool to predict which heart-failure patients...
Real-World Data Demonstrates Success Of Smart Pass Filter on Boston Scientific S-ICD System
News | Implantable Cardioverter Defibrillator (ICD) | May 16, 2018
Boston Scientific announced results from an analysis of the LATITUDE database evaluating the successful reduction of...
Online Message Board Advice on ICDs Reflects Inaccuracies
News | Implantable Cardioverter Defibrillator (ICD) | April 13, 2018
April 13, 2018 — Medical advice about implanted cardiac defibrillators obtained via an online message board appears t
Biotronik U.S. to Distribute Aziyo ECM Envelopes
News | Implantable Cardioverter Defibrillator (ICD) | April 12, 2018
Biotronik U.S. and Aziyo announced a strategic agreement allowing Biotronik to distribute Aziyo's CanGaroo...
Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD) | September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD) | September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Predictive Models May Help Determine Which Patients Benefit From ICDs
News | Implantable Cardioverter Defibrillator (ICD) | July 06, 2017
Two predictive models may help cardiologists decide which patients would most benefit from an implantable cardioverter...
Videos | Implantable Cardioverter Defibrillator (ICD) | June 01, 2017
Lucas Boersma, M.D., Ph.D., FESC, St.
Overlay Init